NeuroOne's story was extraordinary โ a platform for next-generation electrode technology with FDA pathway momentum. But small-cap MedTech is a hard sell to retail without a sophisticated education campaign. GateWatch.Ai told us exactly where the knowledge gaps were. We filled them.
GateWatch.Ai analysis showed that $NMTC bears were concentrated in one recurring theme: regulatory uncertainty. We didn't ignore it โ we addressed it head-on. A three-part Reddit series walked through the FDA submission pathway, historical approval rates for similar device classifications, and NeuroOne's clinical data in plain language.
Posts were distributed across r/biotech, r/investing, and r/Stocks โ each calibrated for the sophistication level of that subreddit's audience. Sophisticated biotech readers got the technical version; general investors got the catalyst timeline. Retail investor mention volume for $NMTC grew 156% over the eight-week campaign.
We recruited healthcare-focused KOLs โ medical device analysts, biotech commentators, and healthcare policy voices โ to contextualise NeuroOne's technology within the broader neuromodulation market. This positioned $NMTC as a category play, not just a single-product bet.
A thread series on the global electrode technology market, co-created with a KOL specialising in neurology devices, became the campaign's highest-performing asset โ generating 280K impressions from an audience that was genuinely interested in the science, not just the ticker.
We hosted four live sessions inside StoryTrading โ one per month โ featuring NeuroOne's management and, in one session, an independent neurologist who could speak to the clinical significance of the technology. Each session ran 60โ90 minutes with unfiltered Q&A.
The independent medical perspective was particularly effective: retail investors trust third-party clinical validation more than company messaging. GateWatch.Ai measured a sentiment score lift of 11 points in the week following each session.
Catalyst windows are the highest-risk, highest-reward moments in small-cap biotech. GateWatch.Ai monitored $NMTC's Stocktwits sentiment daily and flagged when it began drifting negative in the weeks before a key data readout โ typically a sign that uninformed short pressure was building.
We responded with a targeted Stocktwits educational campaign focused on historical data readout outcomes for comparable devices. Bull sentiment recovered ahead of the catalyst, and $NMTC entered the news cycle from a position of retail strength rather than weakness.
NeuroOne entered its key catalyst window with the strongest retail sentiment profile in its trading history. The educational foundation built across Reddit, Discord, X, and Stocktwits meant that retail investors were informed participants in the news cycle โ not reactive, not confused. GateWatch.Ai's pre-catalyst monitoring gave the IR team real-time visibility into retail positioning for the first time.
โ Back to Track Record